Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

28 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Varicella zoster-associated acute retinal necrosis and central nervous system complications in natalizumab treated MS patients.
van Kempen ZLE, van Rossum JA, Hoogervorst E, Strijbis E, Toorop A, Bosscha MI, Frequin S, Dam-van Loon NT, Wattjes MP, Murk JL, Killestein J, Uitdehaag BMJ. van Kempen ZLE, et al. Among authors: toorop a. Mult Scler Relat Disord. 2021 May;50:102838. doi: 10.1016/j.msard.2021.102838. Epub 2021 Feb 10. Mult Scler Relat Disord. 2021. PMID: 33609925
Ocrelizumab after natalizumab in JC-virus positive relapsing remitting multiple sclerosis patients.
van Lierop Z, Toorop AA, Coerver E, Willemse E, Strijbis E, Kalkers NF, Moraal B, Barkhof F, Teunissen CE, Killestein J, van Kempen Z. van Lierop Z, et al. Among authors: toorop aa. Mult Scler J Exp Transl Clin. 2021 Jun 1;7(2):20552173211013831. doi: 10.1177/20552173211013831. eCollection 2021 Apr-Jun. Mult Scler J Exp Transl Clin. 2021. PMID: 34123391 Free PMC article.
Personalized B-cell tailored dosing of ocrelizumab in patients with multiple sclerosis during the COVID-19 pandemic.
van Lierop ZY, Toorop AA, van Ballegoij WJ, Olde Dubbelink TB, Strijbis EM, de Jong BA, van Oosten BW, Moraal B, Teunissen CE, Uitdehaag BM, Killestein J, Kempen ZLV. van Lierop ZY, et al. Among authors: toorop aa. Mult Scler. 2022 Jun;28(7):1121-1125. doi: 10.1177/13524585211028833. Epub 2021 Jul 9. Mult Scler. 2022. PMID: 34240631 Free PMC article.
Longitudinal humoral response after SARS-CoV-2 vaccination in ocrelizumab treated MS patients: To wait and repopulate?
van Kempen ZLE, Wieske L, Stalman EW, Kummer LYL, van Dam PJ, Volkers AG, Boekel L, Toorop AA, Strijbis EMM, Tas SW, Wolbink GJ, Löwenberg M, van Sandt C, Ten Brinke A, Verstegen NJM, Steenhuis M, Kuijpers TW, van Ham SM, Rispens T, Eftimov F, Killestein J; T2B! immunity against SARS-CoV-2 study group. van Kempen ZLE, et al. Among authors: toorop aa. Mult Scler Relat Disord. 2022 Jan;57:103416. doi: 10.1016/j.msard.2021.103416. Epub 2021 Nov 23. Mult Scler Relat Disord. 2022. PMID: 34847379 Free PMC article.
Extended dosing of monoclonal antibodies in multiple sclerosis.
van Kempen ZL, Toorop AA, Sellebjerg F, Giovannoni G, Killestein J. van Kempen ZL, et al. Among authors: toorop aa. Mult Scler. 2022 Nov;28(13):2001-2009. doi: 10.1177/13524585211065711. Epub 2021 Dec 24. Mult Scler. 2022. PMID: 34949134 Review.
The wearing-off phenomenon of ocrelizumab in patients with multiple sclerosis.
Toorop AA, van Lierop ZYGJ, Strijbis EMM, Teunissen CE, Barkhof F, Uitdehaag BMJ, van Kempen ZLE, Killestein J. Toorop AA, et al. Mult Scler Relat Disord. 2022 Jan;57:103364. doi: 10.1016/j.msard.2021.103364. Epub 2021 Nov 1. Mult Scler Relat Disord. 2022. PMID: 35158470 Free article.
Neurofilament-light and contactin-1 association with long-term brain atrophy in natalizumab-treated relapsing-remitting multiple sclerosis.
van Lierop ZY, Noteboom S, Steenwijk MD, van Dam M, Toorop AA, van Kempen ZL, Moraal B, Barkhof F, Uitdehaag BM, Schoonheim MM, Teunissen CE, Killestein J. van Lierop ZY, et al. Among authors: toorop aa. Mult Scler. 2022 Dec;28(14):2231-2242. doi: 10.1177/13524585221118676. Epub 2022 Sep 3. Mult Scler. 2022. PMID: 36062492 Free PMC article.
Ocrelizumab Concentration Is a Good Predictor of SARS-CoV-2 Vaccination Response in Patients with Multiple Sclerosis.
van Kempen ZLE, Hogenboom L, Toorop AA, Steenhuis M, Stalman EW, Kummer LYL, van Dam KPJ, Bloem K, Ten Brinke A, van Ham SM, Kuijpers TW, Wolbink GJ, Loeff FC, Wieske L, Eftimov F, Rispens T, Strijbis EMM, Killestein J; T2B! immunity against SARS-CoV-2 study group. van Kempen ZLE, et al. Among authors: toorop aa. Ann Neurol. 2023 Jan;93(1):103-108. doi: 10.1002/ana.26534. Epub 2022 Nov 2. Ann Neurol. 2023. PMID: 36250739 Free PMC article.
28 results